Menu
What we do
Portfolio
News
Who we are
About
Team
Contact
Newsletter Sign Up
Logins
LP Login
Phase 2 Data Demonstrate Potential of Vergent Biosciences’ Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries
Windham Venture Partners
|
September 11, 2023
Explore More
No items found.